Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lymphoma gene study seeks clues for better treatment

NCT ID NCT06588205

Knowledge-focused Sponsor: Fondazione Italiana Linfomi - ETS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study observes 200 people with diffuse large B-cell lymphoma or high-grade B-cell lymphoma to understand how MYC gene changes relate to the disease and the immune environment. Researchers will review medical records and collect samples to find patterns that may guide future treatments. Participants must have a MYC alteration and have received treatment aimed at curing the lymphoma.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient affected by DLBCL or HGBL with MYC alterations treated with standard R-chemotherapy regimens as first line treatment

Ages

18 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of nodal and extranodal Diffuse Large B Cell Lymphoma, High Grade B Cell Lymphomas (including low-grade transformed lymphomas; double and triple hit; 11q aberration; not otherwise specified) after 1st January 2019 * Presence of one MYC translocation or gain of copies (GCN: \> 3 copies in more than 30% of the nuclei) or amplification evaluated by FISH * Availability of immunohistochemical analysis of CD10, Bcl6, MUM1, Bcl2, Myc, Ki67 * Have received curative treatment (e.g. R-CHOP, R DA EPOCH, intensified "Burkitt like" chemotherapies) as first-line therapy * Histological material of adequate size and quality to perform histological review with any additional investigations (immunohistochemistry, FISH and other molecular analysis). A FFPE block must be provided for patient enrollment. * Age between 18 and 79 years Exclusion Criteria: * Primary lymphomas of the central nervous system, plasmablastic lymphoma, Burkitt's lymphoma, primary mediastinal B lymphoma * Have received palliative treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diffuse large B-cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma high grade B-cell lymphoma high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diffuse large B-cell lymphoma High grade B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements High-grade B-cell lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    20 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • A.O. Cardinale "G. Panico" - U.O.C Ematologia e Trapianto Midollo Osseo

    RECRUITING

    Tricase, Italy

    Contact Email: •••••@•••••

  • A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia U

    NOT_YET_RECRUITING

    Torino, Italy

  • A.O.U. Ospedali Riuniti delle Marche - Clinica di Ematologia

    RECRUITING

    Ancona, Italy

  • A.O.U. SS. Antonio e Biagio e C. Arrigo - S.C.D.U. Ematologia

    RECRUITING

    Alessandria, Italy

  • A.O.U. di Padova - U.O.C. Ematologia

    NOT_YET_RECRUITING

    Padova, Italy

  • A.O.U.I. di Verona - Ematologia

    NOT_YET_RECRUITING

    Verona, Italy

  • A.S.T. Macerata - U.O.S.D Ematologia

    RECRUITING

    Civitanova Marche, Italy

  • A.S.U. Giuliano Isontina - S.C. Ematologia

    RECRUITING

    Trieste, Italy

  • ARNAS Garibaldi - U.O.C. Ematologia

    RECRUITING

    Catania, Italy

  • ASST Grande Ospedale Metropolitano Niguarda - S.C. Ematologia

    RECRUITING

    Milan, Italy

  • ASST Spedali Civili - S.C. Ematologia

    RECRUITING

    Brescia, Italy

  • AUSL Modena sede di Sassuolo - UOSD di Oncologia Area Sud

    RECRUITING

    Sassuolo, Italy

  • Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia

    RECRUITING

    Florence, Italy

  • I.R.C.C.S. Istituto Oncologico Veneto - U.O.C. Oncoematologia

    NOT_YET_RECRUITING

    Castelfranco Veneto, Italy

  • I.R.C.C.S. Istituto Oncologico Veneto - U.O.C. Oncologia 1

    NOT_YET_RECRUITING

    Padova, Italy

  • I.R.C.C.S. Istituto Tumori Giovanni Paolo II - U.O.C. Ematologia

    RECRUITING

    Bari, Italy

  • I.R.C.C.S. Istituto di Candiolo - FPO

    RECRUITING

    Candiolo, Italy

  • Ospedale Maggiore Policlinico Fondazione IRCCS Ca' Granda - S.C. Ematologia

    RECRUITING

    Milan, Italy

  • U.O.C. Ematologia - A.O.U. Senese

    NOT_YET_RECRUITING

    Siena, Italy

  • ULSS 2 Ospedale Ca' Foncello - U.O.C. Ematologia

    RECRUITING

    Treviso, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.